Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Calithera Biosciences stock

Learn how to easily invest in Calithera Biosciences stock.

Calithera Biosciences Inc is a biotechnology business based in the US. Calithera Biosciences shares (CALA) are listed on the NASDAQ and all prices are listed in US Dollars. Calithera Biosciences employs 63 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Calithera Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CALA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Calithera Biosciences stock price (NASDAQ: CALA)

Use our graph to track the performance of CALA stocks over time.

Calithera Biosciences shares at a glance

Information last updated 2022-07-01.
Latest market close$2.42
52-week range$2.31 - $49.80
50-day moving average $4.11
200-day moving average $15.31
Wall St. target price$35.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-28.78

Buy Calithera Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Calithera Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Calithera Biosciences price performance over time

Historical closes compared with the close of $2.42 from 2022-07-01

1 week (2022-06-28) -15.38%
1 month (2022-06-01) N/A
3 months (2022-04-05) 605.33%
6 months (2022-01-05) 289.69%
1 year (2021-07-02) 18.63%
2 years (2020-07-02) -53.01%
3 years (2019-07-05) 4.48
5 years (2017-07-05) 17.6

Calithera Biosciences financials

Revenue TTM $9.8 million
Gross profit TTM $9.8 million
Return on assets TTM -83.36%
Return on equity TTM -164.78%
Profit margin 0%
Book value $0.11
Market capitalisation $12 million

TTM: trailing 12 months

Calithera Biosciences share dividends

We're not expecting Calithera Biosciences to pay a dividend over the next 12 months.

Have Calithera Biosciences's shares ever split?

Calithera Biosciences's shares were split on a 1:20 basis on 14 June 2022. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Calithera Biosciences shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Calithera Biosciences shares which in turn could have impacted Calithera Biosciences's share price.

Calithera Biosciences share price volatility

Over the last 12 months, Calithera Biosciences's shares have ranged in value from as little as $2.31 up to $49.8. A popular way to gauge a stock's volatility is its "beta".

CALA.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calithera Biosciences's is 1.6266. This would suggest that Calithera Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Calithera Biosciences overview

Calithera Biosciences, Inc. , a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta.

Frequently asked questions

What percentage of Calithera Biosciences is owned by insiders or institutions?
Currently 1.192% of Calithera Biosciences shares are held by insiders and 46.765% by institutions.
How many people work for Calithera Biosciences?
Latest data suggests 63 work at Calithera Biosciences.
When does the fiscal year end for Calithera Biosciences?
Calithera Biosciences's fiscal year ends in December.
Where is Calithera Biosciences based?
Calithera Biosciences's address is: 343 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is Calithera Biosciences's ISIN number?
Calithera Biosciences's international securities identification number is: US13089P5070
What is Calithera Biosciences's CUSIP number?
Calithera Biosciences's Committee on Uniform Securities Identification Procedures number is: 13089P101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site